CAR T-cell therapy (CAR-T) has emerged as a therapeutic option with the ability to infiltrate and modulate the tumor microenvironment and control tumor growth. While normal T-cells with effector features have difficulty infiltrating the complex tumor microenvironment, ex vivo reprogramming of a patient’s own T-cells with a chimeric antigen receptor (CAR) enables the targeting of specific tumor antigens and the appropriate direction of immune responses. Given the reprogramming of a patient’s T-cells, CAR-T cells are advantageous in that they have unique specificity and can control cancer cells that selectively interact with the specific antigen receptor. This ability to target tumors with higher specificity can expedite tumor cell death and eradicate cancer more effectively with longer durations of response.
Assessment of the impact of earlier access to disease-modifying treatments with more convenient administration frequency in reducing the socioeconomic burden for multiple sclerosis patients in Europe
The socioeconomic impact of Multiple Sclerosis (MS) extends to various areas of a patient’s life including personal wellbeing and mental health, family life...